Skip to content

A randomized double-blind controlled clinical study on the effects of qishen yiqi dropping pills on exercise endurance and quality of life in patients with coronary heart disease after interventional therapy

A randomized double-blind controlled clinical study on the effects of qishen yiqi dropping pills on exercise endurance and quality of life in patients with coronary heart disease after interventional therapy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040838
Enrollment
Unknown
Registered
2020-12-11
Start date
2020-12-20
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative coronary heart disease

Interventions

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Have a clear understanding of the research content and purpose, participate in the study voluntarily, and sign the informed consent form by himself / herself; 2. It is consistent with the diagnostic criteria of Western medicine for stable coronary heart disease; 3. Patients with Qi deficiency and blood stasis syndrome who meet the above diagnostic criteria of TCM; 4. Complete the overall treatment plan after PCI; 5. Within 1 week to 6 months after PCI; 6. The age is between 18 and 75 years old.

Exclusion criteria

Exclusion criteria: 1. There are contraindications of cardiopulmonary exercise test; 2. Plan for coronary artery bypass grafting or heart transplantation; 3. Within 3 months before admission: stroke, transient ischemic attack; carotid artery or other major vascular surgery; persistent ventricular tachycardia or ventricular fibrillation; 4. Ventricular arrhythmia was not controlled effectively (antiarrhythmic drugs or implantable defibrillator were ineffective; 5. Uncorrected primary obstruction or severe reflux valvular disease, non dilated (restrictive) or hypertrophic cardiomyopathy; 6. Patients with second or third degree heart block or sick sinus syndrome, without permanent pacemaker, who need implantable devices for heart failure; 7. Obstructive or bronchospasmodic lung disease (such as asthma, bronchitis, etc.) requires oral or inhaled bronchodilator or hormone therapy; 8. Pregnant or lactating women and women who plan to become pregnant during the trial period; 9. Cancer or other systemic diseases, the expected survival time is less than 12 months; 10. Use other clinical trial drugs or participate in medical device test within 30 days before enrollment; 11. The researchers considered that they could not participate in the study after clinical evaluation.

Design outcomes

Primary

MeasureTime frame
Peak oxygen consumption change rate;

Secondary

MeasureTime frame
TCM syndrome score;Indexes of systolic and diastolic function in echocardiography;seattle angina questionnaire;EuroQol-5 Dimensions;routine blood test;Liver and kidney function;blood fat;electrocardiogram;

Countries

China

Contacts

Public ContactLu Xiaoyan

China-Japan Friendship Hospital

deerxiaoyan@126.com+86 13701370868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026